YOUR SUPPORT HELPS CURE CANCER AND RELATED DISEASES. EVERY DOLLAR COUNTS.
You will receive periodic updates from us about the groundbreaking research and progress your support makes possible. You may unsubscribe at any time.
Thank you for your generosity. Your donation WAS MATCHED and is already at work to fuel fearless science.
Thank you for your generosity. Your donation WAS MATCHED and is already at work to fuel fearless science.
Matching Gifts
Your employer may match your gift to Fred Hutch. Enter your employer s name in our search box to find out if your company or organization has a matching gift program.
Slideshow ( 3 images )
OAKLAND, Calif. (Reuters) - Cellares Corp, a cell therapy manufacturing technology startup in South San Francisco, said on Wednesday it raised $82 million in a funding round led by new investor Decheng Capital and existing investor Eclipse Ventures.
The funding will help accelerate development of its “Cell Shuttle” - a machine roughly the size of a small conference room that has all the tools needed to automate manufacturing of cell therapy drugs, according to Cellares CEO and co-founder Fabian Gerlinghaus.
Patients’ cells are loaded into a cartridge and the machine uses a fully automated process to manufacture a cell therapy product ready for infusion back into the patient, he said.
1. Globally, the COVID-19 pandemic is as bad as it has ever been, with a seven-day average of more than 800,000 new cases and 13,000 deaths per day reported. But in the U.S., the "number of reported infections dropped to its lowest point in seven months" on Tuesday, The Washington Post reports. For the first time in 208 days, the daily average of new infections in the U.S. dropped below 50,000. And the last time the average death toll was as low.
MedCity News
Cellares gets $82M to make cell therapy manufacturing automated, scalable
Cell therapy manufacturing is currently a manual, multi-step process that takes weeks. Startup Cellares, which is developing a system that automates the process and makes manufacturing scalable, will use the Series B financing to accelerate its work.
Shares0
Talk to enough biotech industry folks and the phrase “the product is the process” is bound to come up. It refers to cell therapies, which are made by engineering human cells. In short, the medicine is an extension of the process that produced it. Today, that process is time consuming, mostly manual, and very expensive.
E-Mail
Current guidelines for managing osteoporosis specifically call out hip or spine fractures for increasing the risk for subsequent bone breaks. But a new UCLA-led study suggests that fractures in the arm, wrist, leg and other parts of the body should also set off alarm bells.
A fracture, no matter the location, indicates a general tendency to break a bone in the future at a different location, said Dr. Carolyn Crandall, the study s lead author and a professor of medicine at the David Geffen School of Medicine at UCLA. Current clinical guidelines have only been emphasizing hip and spine fractures, but our findings challenge that viewpoint, Crandall said. By not paying attention to which types of fractures increase the risk of future fractures, we are missing the opportunity to identify people at increased risk of future fracture and counsel them regarding risk reduction.